Characteristics of the 22 patients, changes in indices of efficacy from day 1 to day 14 in the two groups, and comparison of the improvement between the groups
| Group A (n=10) | Group B (n=12) | Group A v B p value3-150 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | Day 14 | Difference between day 14 and day 1 | p value | Day 1 | Day 14 | Difference between day 14 and day 1 | p value | |||
| W/H (%) | 96.4 (11.6) | 100.4 (11.5) | 3.96 (2.63) | <0.001 | 93.2 (11.7) | 96.3 (15) | 3.14 (4.35) | <0.002 | 0.6 | |
| Prealb (mg/l) | 194 (70) | 260 (54) | 65.8 (67) | <0.05 | 170 (45) | 233 (60) | 63.4 (51.4) | <0.002 | 0.09 | |
| WBC (×109/l) | 11.3 (4.9) | 7.9 (2.5) | 3.44 (3.84) | <0.05 | 10.2 (4.4) | 6.4 (1.4) | 3.81 (3.38) | <0.004 | 0.8 | |
| PMN (×109/l) | 7.3 (3.9) | 4.2 (2.0) | 3.05 (3.38) | <0.05 | 6.5 (3.6) | 3.3 (1) | 3.18 (3.10) | <0.01 | 0.9 | |
| FVC (%) | 61 (18) | 75 (28) | 13.8 (15) | <0.05 | 72 (21) | 83 (20) | 10.5 (13) | <0.05 | 0.6 | |
| FEV1 (%) | 50 (19) | 65 (29) | 14.9 (16) | <0.05 | 61 (22) | 75 (22) | 14 (15.3) | <0.05 | 0.9 | |
| FEF 25–75 (%) | 32 (16) | 45 (27) | 12.9 (14.8) | <0.05 | 38 (21) | 59 (22) | 21 (22) | <0.02 | 0.3 | |
| HR (beats/min) | 100 (14) | 86 (7) | −14 (9) | <0.001 | 91 (15) | 77 (12) | −14 (19) | <0.05 | 0.9 | |
| RR (breaths/min) | 30 (7) | 24 (4) | −6 (4) | <0.003 | 33 (16) | 21 (5) | −12 (14) | <0.05 | 0.2 | |
Group A, thrice daily infusions of tobramycin; group B, once daily infusions of tobramycin. Values are mean (SD).
↵3-150 Comparison of improvements between groups A and B.
FEF 25–75, forced expiratory flow between 25% and 75% of forced vital capacity; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; HR, heart rate; PMN, polymorphonuclear neutrophil cells; Prealb, prealbumin; RR, respiratory rate; WBC, white blood cells; W/H, weight/height ratio; %, per cent of predicted values.